On January 25, 2023 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, reported the publication of a preclinical study demonstrating delta-like ligand 3 (DLL3) is a promising tumor target for AlloCAR T in small cell lung cancer (SCLC) (Press release, Allogene, JAN 25, 2023, View Source [SID1234626530]). The findings were published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SCLC is an aggressive disease with limited treatment options. Approximately 30,000 patients in the United States are affected each year with this disease which has a 5-year overall survival rate of approximately 7%.1 DLL3, with high expression on tumors and limited expression in normal tissue, is a promising target for SCLC and potentially other solid tumors.
"As a leader in allogeneic CAR T research and development, we are committed to exploring the potential of this therapeutic modality across a broad range of indications, including in solid tumors where there is significant need," said Barbra Sasu, Ph.D., Chief Scientific Officer at Allogene.
This study describes the selection of ALLO-213 as an allogeneic CAR T development candidate targeting DLL3 from a large number of single chain variable fragment (scFv)-based anti-DLL3 CAR candidates. The selection of ALLO-213 was based on potency and specificity against SCLC cell lines in vitro and in vivo, including cell lines with very low antigen density to establish sensitivity. The results from the pre-clinical study showed:
No DLL3 on target toxicity was observed in preclinical models supporting a potentially attractive safety profile
Clinical DLL3 CAR candidates controlled DLL3+ tumor growth in mice without normal tissue toxicity